Status: Recruiting
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.
Participants needed: 516
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai JMT-Bio Inc.Updated: Dec 16, 2024Locations: 1
Eligibility criteria
Be able to understand and voluntarily sign the written informed consent form (IC... [+10]
Participants with concomitant mutations such as ALK, ROS1, KRAS, BRAF, RET, MET,... [+5]